A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)
PHASE2CompletedINTERVENTIONAL
Enrollment
132
Participants
Timeline
Start Date
November 30, 2003
Study Completion Date
August 31, 2005
Conditions
Myelodysplastic Syndromes
Interventions
DRUG
Daclizumab
Trial Locations (1)
20892
National Heart, Lung and Blood Institute (NHLBI), Bethesda
All Listed Sponsors
lead
National Heart, Lung, and Blood Institute (NHLBI)
NIH
NCT00072969 - A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS) | Biotech Hunter | Biotech Hunter